KT Medical Service PCL vs Fresenius Medical Care AG & Co. KGaA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

KT Medical Service PCL (KTMS.BK)

Q3 202619 Aug – 4 Oct 2026

▲3▼1

KTMS expands dialysis network; licensing delays shift revenue timing

Strong core dialysis growth and expansion KTMS's core hemodialysis revenue rose 9.34% in H1 2026 on more patients and new branches. It plans to add 3-5 units and 36-64 machines in H2, targeting 800 million baht revenue for 2026. This growth supports a higher share price.
It shows the main business is growing and expanding, directly driving future revenue and profit.
High demand for dialysis services Thailand has about 8 million people at risk of kidney disease and 120,000 needing dialysis, with 80% choosing hemodialysis. KTMS's new branches already run at over 80% utilisation, showing strong demand that can lift future earnings.
It explains the underlying demand that supports KTMS's expansion and revenue targets.
Licensing delays push back revenue Government licensing for new dialysis branches now takes about 120 days, up from 90 days. This delays when new branches can start earning money, so some revenue expected earlier may come later. It's a timing issue, not a loss of revenue.
It is a real counterweight that could slow near-term revenue recognition and pressure the stock.
Q4 2026 outlook improves as branches open KTMS expects better Q4 2026 results as new branches gradually open and utilisation stays at least 80%. This suggests revenue will accelerate once licensing clears, supporting the stock.
It gives a forward-looking positive catalyst that could drive the stock higher.

September 202619 Aug – 4 Oct 2026

▲3▼1

KTMS expands dialysis network; licensing delays shift revenue timing

Strong core dialysis growth and expansion KTMS's core hemodialysis revenue rose 9.34% in H1 2026 on more patients and new branches. It plans to add 3-5 units and 36-64 machines in H2, targeting 800 million baht revenue for 2026. This growth supports a higher share price.
It shows the main business is growing and expanding, directly driving future revenue and profit.
High demand for dialysis services Thailand has about 8 million people at risk of kidney disease and 120,000 needing dialysis, with 80% choosing hemodialysis. KTMS's new branches already run at over 80% utilisation, showing strong demand that can lift future earnings.
It explains the underlying demand that supports KTMS's expansion and revenue targets.
Licensing delays push back revenue Government licensing for new dialysis branches now takes about 120 days, up from 90 days. This delays when new branches can start earning money, so some revenue expected earlier may come later. It's a timing issue, not a loss of revenue.
It is a real counterweight that could slow near-term revenue recognition and pressure the stock.
Q4 2026 outlook improves as branches open KTMS expects better Q4 2026 results as new branches gradually open and utilisation stays at least 80%. This suggests revenue will accelerate once licensing clears, supporting the stock.
It gives a forward-looking positive catalyst that could drive the stock higher.

Latest19 Aug – 4 Oct 2026

▲3▼1

KTMS expands dialysis network; licensing delays shift revenue timing

Strong core dialysis growth and expansion KTMS's core hemodialysis revenue rose 9.34% in H1 2026 on more patients and new branches. It plans to add 3-5 units and 36-64 machines in H2, targeting 800 million baht revenue for 2026. This growth supports a higher share price.
It shows the main business is growing and expanding, directly driving future revenue and profit.
High demand for dialysis services Thailand has about 8 million people at risk of kidney disease and 120,000 needing dialysis, with 80% choosing hemodialysis. KTMS's new branches already run at over 80% utilisation, showing strong demand that can lift future earnings.
It explains the underlying demand that supports KTMS's expansion and revenue targets.
Licensing delays push back revenue Government licensing for new dialysis branches now takes about 120 days, up from 90 days. This delays when new branches can start earning money, so some revenue expected earlier may come later. It's a timing issue, not a loss of revenue.
It is a real counterweight that could slow near-term revenue recognition and pressure the stock.
Q4 2026 outlook improves as branches open KTMS expects better Q4 2026 results as new branches gradually open and utilisation stays at least 80%. This suggests revenue will accelerate once licensing clears, supporting the stock.
It gives a forward-looking positive catalyst that could drive the stock higher.

Fresenius Medical Care AG & Co. KGaA (FME.XETRA)

Q3 202620 Jul – 7 Oct 2026

▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.
This is the core financial result that directly drives investor confidence and the stock's valuation.
New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.
New products and clinical evidence can open new markets and increase demand for the company's treatments.
China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.
The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.
CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.
A CEO change is a major event that can affect investor sentiment and future strategy.

August 202620 Jul – 7 Oct 2026

▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.
This is the core financial result that directly drives investor confidence and the stock's valuation.
New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.
New products and clinical evidence can open new markets and increase demand for the company's treatments.
China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.
The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.
CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.
A CEO change is a major event that can affect investor sentiment and future strategy.

Latest20 Jul – 7 Oct 2026

▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.
This is the core financial result that directly drives investor confidence and the stock's valuation.
New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.
New products and clinical evidence can open new markets and increase demand for the company's treatments.
China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.
The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.
CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.
A CEO change is a major event that can affect investor sentiment and future strategy.